{"disease":{"id":"malignancy","name":"malignancy","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":28},"drugs":{"marketed":[{"drug_id":"zoledronic-acid","indication_name":"Hypercalcemia of Malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zometa","generic_name":"ZOLEDRONIC ACID","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"zoledronic acid","quality_score":80,"revenue":null,"mechanism":"Zometa works by inhibiting the enzyme farnesyl pyrophosphate synthase, which is involved in the mevalonate pathway and ultimately leads to the inhibition of osteoclast activity."},{"drug_id":"ethacrynic-acid","indication_name":"Ascites Due to Malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Edecrin","generic_name":"ETHACRYNIC ACID","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Glutathione S-transferase P","drug_class":"Loop Diuretic [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"fludeoxyglucose-f-18","indication_name":"Oncology - Malignancy Evaluation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FLUDEOXYGLUCOSE F 18","company_name":"","drug_phase":"marketed","molecular_target":"glucose transporter proteins, hexokinase, glucose-6-phosphatase","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":40,"revenue":null,"mechanism":"Fludeoxyglucose F-18 is a glucose analog that accumulates in cells with high glucose metabolism, reflecting metabolic activity."},{"drug_id":"fludeoxyglucose","indication_name":"malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludeoxyglucose F-18","generic_name":"FLUDEOXYGLUCOSE","company_name":"Downstate Clincl","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":44,"revenue":null,"mechanism":"Fludeoxyglucose F-18 is a radioactive sugar molecule that accumulates in cells with high metabolic activity, allowing for visualization of cancer and other conditions."},{"drug_id":"etidronic-acid","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Didronel","generic_name":"ETIDRONIC ACID","company_name":"Procter And Gamble","drug_phase":"marketed","molecular_target":"","drug_class":"Bisphosphonate","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-succinate","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solu-Cortef","generic_name":"hydrocortisone succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"f-18","indication_name":"malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludeoxyglucose F-18","generic_name":"F-18","company_name":"3D Imaging Drug","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":44,"revenue":null,"mechanism":"Fludeoxyglucose F-18 is a radioactive molecule that accumulates in areas of high metabolic activity, allowing for imaging of various conditions."},{"drug_id":"incadronic-acid","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bisphonal","generic_name":"INCADRONIC ACID","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"incadronic acid","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-acetate","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortifoam","generic_name":"HYDROCORTISONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"heparin","indication_name":"Prevention of Recurrent Venous Thrombosis Associated with Malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"HEPARIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Anti-coagulant","quality_score":56,"revenue":null,"mechanism":"Heparin works by binding to Antithrombin-III, a protein that inhibits the formation of blood clots."},{"drug_id":"cortisone-acetate","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"cisplatin","indication_name":"Invasive Bladder Malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Platinol-Aq","generic_name":"cisplatin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Platinum-based Drug [EPC]","quality_score":52,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-acetate","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celestone Soluspan","generic_name":"BETAMETHASONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"neridronic-acid","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neridronate","generic_name":"NERIDRONIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"neridronic acid","quality_score":33,"revenue":null,"mechanism":"Neridronate works by inhibiting the enzyme Farnesyl pyrophosphate synthase, which plays a crucial role in bone resorption."},{"drug_id":"ethidronate","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ethidronate","company_name":"Centre National d'Etudes Spatiales","drug_phase":"phase_1","molecular_target":"Type IV secretion-like conjugative transfer relaxase protein TraI","drug_class":"","quality_score":7,"revenue":null,"mechanism":""},{"drug_id":"adriacin","indication_name":"Invasive Bladder Malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunorubicin","indication_name":"Invasive Bladder Malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pamidronate","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pamidronate","company_name":"US Department of Veterans Affairs","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Hypoxanthine-guanine phosphoribosyltransferase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"prednison","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"heparin-sodium","indication_name":"Prevention of Recurrent Venous Thrombosis Associated with Malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"Heparin Sodium","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Antithrombin III, Coagulation Factors Xa and IIa","drug_class":"Anticoagulant","quality_score":63,"revenue":null,"mechanism":"Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa."},{"drug_id":"methylprednisolone","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"hydrocortisone","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pamidronic-acid","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aredia","generic_name":"PAMIDRONIC ACID","company_name":"","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"Bisphosphonate","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"technetium","indication_name":"malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Technetium Tc 99M Sestamibi","generic_name":"TECHNETIUM","company_name":"Cyclomedica","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":44,"revenue":null,"mechanism":"Technetium Tc 99m Sestamibi accumulates in viable myocardial tissue similar to thallous chloride TI-201, with possible mitochondrial retention."},{"drug_id":"methylprednisolone-acetate","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depo-Medrol","generic_name":"METHYLPREDNISOLONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Depo-Medrol works by binding to the glucocorticoid receptor, which then regulates the expression of genes involved in inflammation and immune response."},{"drug_id":"liposomal-doxorubicin","indication_name":"Invasive Bladder Malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"zoledronic-acid","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zometa","generic_name":"ZOLEDRONIC ACID","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"zoledronic acid","quality_score":80,"revenue":null,"mechanism":"Zometa works by inhibiting the enzyme farnesyl pyrophosphate synthase, which is involved in the mevalonate pathway and ultimately leads to the inhibition of osteoclast activity."},{"drug_id":"betamethasone","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"doxorubicin","indication_name":"Invasive Bladder Malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"cortisol","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"hydroxydaunomycin","indication_name":"Invasive Bladder Malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zometa","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zometa","company_name":"University of Arkansas","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"neridronate","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neridronate","company_name":"Ente Ospedaliero Ospedali Galliera","drug_phase":"phase_3","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Invasive Bladder Malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zoledronate","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zoledronate","company_name":"Children's Hospital Medical Center, Cincinnati","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"etidronate","indication_name":"Humoral hypercalcemia of malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Etidronate","company_name":"Organon and Co","drug_phase":"phase_3","molecular_target":"Type IV secretion-like conjugative transfer relaxase protein TraI","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":42,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04991922","title":"BostonGene-Integrated Genomic Registry (BIGR)","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"BostonGene","has_results":false},{"nct_id":"NCT04679675","title":"Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":32771,"lead_sponsor_name":"Kaiser Permanente","has_results":true},{"nct_id":"NCT04466059","title":"Better Leukemia Diagnostics Through AI (BELUGA)","phase":"","overall_status":"RECRUITING","enrollment_count":25000,"lead_sponsor_name":"Munich Leukemia Laboratory","has_results":false},{"nct_id":"NCT06224452","title":"Is Ibrutinib-related Atrial Fibrillation Dose Dependent","phase":"","overall_status":"UNKNOWN","enrollment_count":18000,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT06416761","title":"Genetics in the Progression of Nephropathies","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Ospedale San Raffaele","has_results":false},{"nct_id":"NCT05889806","title":"AUD Biomarkers Study (Proteomic and Genomic Analysis of Biospecimens)","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":10000,"lead_sponsor_name":"Audubon Bioscience","has_results":false},{"nct_id":"NCT04496375","title":"An Evaluation of Patients Access to Their Electronic Medical Records Via the IPC Connect Application","phase":"","overall_status":"UNKNOWN","enrollment_count":8000,"lead_sponsor_name":"Institut Paoli-Calmettes","has_results":false},{"nct_id":"NCT03736824","title":"Correlation of Endoscopic Findings and Symptoms in Patients Undergoing the First Upper Gastrointestinal Endoscopy","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT05463796","title":"InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT05598879","title":"Global Cardio Oncology Registry","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"The Cleveland Clinic","has_results":false},{"nct_id":"NCT02996903","title":"Prospective Multicenter Registry On RadiaTion Dose Estimates Of Cardiac CT AngIOgraphy IN Daily Practice in 2017","phase":"","overall_status":"COMPLETED","enrollment_count":4502,"lead_sponsor_name":"LMU Klinikum","has_results":false},{"nct_id":"NCT05695638","title":"Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Morten Ladekarl","has_results":false},{"nct_id":"NCT05735704","title":"Early Detection and Screening of Hematological Malignancies - SANGUINE","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"JaxBio Ltd","has_results":false},{"nct_id":"NCT03381053","title":"Study to Compare Pathologic Type, NIH and WHO Criteria,and Mechanism of GIST Malignant Transformation","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT02958462","title":"Pre-myeloid Cancer and Bone Marrow Failure Clinic Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03546101","title":"Early Detection of Epstein-Barr Virus Related Disease.","phase":"","overall_status":"COMPLETED","enrollment_count":1527,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT06116032","title":"Immune Profiling for Cancer Immunotherapy Response","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Dartmouth-Hitchcock Medical Center","has_results":false},{"nct_id":"NCT03855969","title":"Central Venous Access Device Removal in Cancer Patients","phase":"","overall_status":"COMPLETED","enrollment_count":1402,"lead_sponsor_name":"General Hospital Groeninge","has_results":false},{"nct_id":"NCT03992352","title":"Composite Health Assessment Risk Model (CHARM) for Older Adults (BMT CTN 1704)","phase":"","overall_status":"COMPLETED","enrollment_count":1229,"lead_sponsor_name":"Center for International Blood and Marrow Transplant Research","has_results":false},{"nct_id":"NCT05600933","title":"Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1200,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06665776","title":"HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"PharmaEssentia","has_results":false},{"nct_id":"NCT04948762","title":"A Contemporary Review of Surgical Approaches in Pelvic Exenterative Surgery","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"St Vincent's University Hospital, Ireland","has_results":false},{"nct_id":"NCT04852796","title":"Efficacy and Safety of the Anti- COVID-19 Vaccin in Clinical Hematology Patients","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Centre Hospitalier de Cornouaille","has_results":false},{"nct_id":"NCT05713214","title":"Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT05210348","title":"Clinical Evaluation of Detection of High Risk HPV in Urine","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT05973487","title":"A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":840,"lead_sponsor_name":"TScan Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05819762","title":"Evaluation of ClearLLab LS Screening Panel","phase":"","overall_status":"COMPLETED","enrollment_count":831,"lead_sponsor_name":"Beckman Coulter, Inc.","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05396157","title":"Venous Thromboembolism in Hematologic Malignancy and Hematopoietic Cell Transplant Patients: a Retrospective Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":813,"lead_sponsor_name":"Mount Sinai Hospital, Canada","has_results":false},{"nct_id":"NCT01231347","title":"QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"NantCell, Inc.","has_results":true},{"nct_id":"NCT07249138","title":"Impact of Congenital Heart Disease on the Prognosis of Childhood Hematological Neoplasms: A Multicenter Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"Children's Hospital of Fudan University","has_results":false},{"nct_id":"NCT05817110","title":"Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule.","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":712,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06487247","title":"HEME Home Transfusion Program","phase":"NA","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT05270096","title":"International Leukemia Target Board","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Princess Maxima Center for Pediatric Oncology","has_results":false},{"nct_id":"NCT02214134","title":"SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access","phase":"","overall_status":"COMPLETED","enrollment_count":539,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":false},{"nct_id":"NCT05467449","title":"DxFLEX 10C Clinical Study","phase":"","overall_status":"COMPLETED","enrollment_count":527,"lead_sponsor_name":"Beckman Coulter, Inc.","has_results":false},{"nct_id":"NCT03960593","title":"Cohort of Patients Over 70 Years of Age With Cancer and / or Hematological Malignancy","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false},{"nct_id":"NCT05749302","title":"Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT05510908","title":"Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC","phase":"","overall_status":"COMPLETED","enrollment_count":460,"lead_sponsor_name":"AIDS Malignancy Consortium","has_results":true},{"nct_id":"NCT04341974","title":"Perioperative Use of Serum Creatinine and Postoperative Acute Kidney Injury","phase":"","overall_status":"COMPLETED","enrollment_count":423,"lead_sponsor_name":"Careggi Hospital","has_results":false},{"nct_id":"NCT03449953","title":"Critical Care Outcomes of Hematologic Oncology Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":415,"lead_sponsor_name":"Mount Sinai Hospital, Canada","has_results":false},{"nct_id":"NCT03727009","title":"Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies","phase":"","overall_status":"TERMINATED","enrollment_count":409,"lead_sponsor_name":"Exact Sciences Corporation","has_results":false},{"nct_id":"NCT03800758","title":"Expressive Helping for Stem Cell Transplant Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":405,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT05761366","title":"Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04466137","title":"Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":398,"lead_sponsor_name":"Xiamen Amoytop Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT03561727","title":"Risk Factors for Development of Incisional Hernia in Transverse Incisions","phase":"NA","overall_status":"UNKNOWN","enrollment_count":392,"lead_sponsor_name":"Medical University of Warsaw","has_results":false},{"nct_id":"NCT03498183","title":"Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (≥15 mm) Classified Bethesda III or IV on Cytology","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":372,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT03806764","title":"Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient","phase":"NA","overall_status":"UNKNOWN","enrollment_count":370,"lead_sponsor_name":"Melbourne Health","has_results":false},{"nct_id":"NCT05551832","title":"Prevalence of Marginal Ulcer After PPPD and Preventive Effect of Proton Pump Inhibitor in Korea: A Prospective Multicenter Study","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":360,"lead_sponsor_name":"Gangnam Severance Hospital","has_results":false},{"nct_id":"NCT06960993","title":"Mosaic Trial for Stem Cell Transplant Recipients","phase":"NA","overall_status":"RECRUITING","enrollment_count":356,"lead_sponsor_name":"Northwestern University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}